K-232 phase 3 long-term administration study in patients with primary open-angle glaucoma (POAG), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension (OH)
Latest Information Update: 13 Oct 2024
At a glance
- Drugs Brimonidine/ripasudil (Primary)
- Indications Desquamation; Glaucoma; Ocular hypertension; Pigmentary glaucoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Kowa
Most Recent Events
- 01 Aug 2024 Primary endpoint has been met (Efficacy :Mean IOP reduction from baseline at all measurement points) , according to Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 01 Aug 2024 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 11 Jan 2022 New trial record